Case of autoimmune hepatitis with markedly enlarged hepatoduodenal ligament lymph nodes

Table 1 Laboratory data of the patient on admission

WBC	2460/μL	IL-2	1.5 U/mL
Neut	65%	IL-6	7.4 pg/mL (0-4.0 pg/mL)
Lym	20%	IgG	3814 mg/dL (820-1740 mg/dL)
Mono	13%	IgA	298 mg/dL (90-400 mg/dL)
RBC	313 × 104/μL	IgM	1738 mg/dL (31-200 mg/dL)
Hb	10.1 g/dL	IgG4	97 mg/dL (4-108 mg/dL)
Plt	17.5 × 104/μL	ANA	× 2560
PT-INR	1.2	AMA	(-)
TP	8.9 g/dL	Antismooth muscle antibody	(-)
Alb	2.7 g/dL
T-Bil	15.6 mg/dL	sIL2R	2550 U/mL
D-Bil	12.4 mg/dL	HA IgM-Ab	(-)
ALP	847 IU/L	HBsAg	(-)
γ-GTP	91 IU/L	HBcAb	(-)
AST	1068 IU/L	IgM-HBcAb	(-)
ALT	696 IU/L	HCVAb	(-)
LDH	455 IU/L	HCV-RNA	(-)
ChE	130 IU/L	Fourth-generation HIV screening assay	(-)
Tch	146 mg/dL
CPK	63 IU/L
CRP	0.70 mg/dL	EBV VCA-IgM	(-)
FBS	95 mg/dL	EBV VCA-IgG	(+)
Ferritin	504 ng/mL	CMV-IgM	2.06
Serum copper	177 μg/dL	CMV-IgG	(-)
Ceruloplasmin	40.2 mg/dL	pp65 antigenemia method	(-)

WBC: White blood cell; RBC: Red blood cell; PT/INR: Prothrombin time/international normalized ratio; ALP: Alkaline phosphatase; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; LDH: Lactic dehydrogenase; CPK: Creatine phosphokinase; CRP: cAMP receptor protein; FBS: Fatal bovine serum; IL: Interleukin; ANA: Anti-nuclear antibody; AMA: Anti-mitochondrial antibody; sIL-2R: Soluble interleukin-2 receptor; Ig: Immunoglobulin; HA-IgM: Hepatitis A virus IgM; HBsAg: Hepatitis B surface antigen; HBcAb: Anti-hepatitis B core antibody; HCV: Hepatitis C virus; EBV VCA: Epstein-barr virus viral capsid antigen; CMV: Cytomegalovirus; HIV: Human immunodeficiency virus.